Advertisement
Teva
Subscribe to Teva

The Lead

Teva Announces Sale of Sellersville, PA Facility

March 2, 2015 8:44 am | News | Comments

Teva Pharmaceutical Industries today announced that it has signed an agreement to sell its Sellersville, Pennsylvania facility to G&W Laboratories, Inc. This sale supports its plans to streamline operations by reducing excess manufacturing capacity and is part of the company’s previously announced cost reduction program.

FDA Accepts Teva's NDA for Abuse-Deterrent Opioid

February 25, 2015 10:03 am | News | Comments

Teva Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) has...

Watchdog Group Seeks US Ban of Antifungal Tablets

February 24, 2015 11:34 am | News | Comments

A consumer safety group is calling on the U.S Food and Drug Administration to pull certain...

FDA Approves Teva's Generic Nexium® Delayed-Release Capsules

January 27, 2015 7:06 am | News | Comments

Teva Pharmaceutical has announced the Food and Drug Administration (FDA) approval of the first...

View Sample

FREE Email Newsletter

Fitch: SCOTUS Extends Patent Benefit for Teva; Generics Lose for Now

January 22, 2015 8:20 am | News | Comments

The Supreme Court (SCOTUS) decision that a federals appeals court wrongly overturned Teva Pharmaceutical's (Teva) Copaxone patent is a positive credit development for the drug maker, according to Fitch Ratings.       

Supreme Court Sides with Teva in Drug Dispute

January 21, 2015 8:11 am | by SAM HANANEL, Associated Press | News | Comments

The U.S. Supreme Court on Tuesday sided with Teva Pharmaceutical in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug. The justices ruled 7-2 that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone.

OncoGenex to Regain Rights to Custirsen from Teva

January 2, 2015 8:56 am | News | Comments

OncoGenex Pharmaceuticals has executed an initial agreement with Teva Pharmaceutical Industries to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.

Advertisement

Teva’s GRANIX® Injection Approved for Self-Administration

December 23, 2014 8:17 am | News | Comments

Teva Pharmaceutical has announced that the FDA has approved GRANIX® Injection for self-administration by patients and caregivers. With the approval of this additional administration option, physicians will soon have the flexibility to prescribe GRANIX for either in-office or at home use.

GlobalData: Patent Cliff Means Pharmaceutical Companies Will Lose $65B by 2019

December 10, 2014 9:24 am | News | Comments

Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.

Supreme Court Weighs Generic Drug Dispute

October 15, 2014 1:28 pm | by SAM HANANEL, Associated Press | News | Comments

The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.             

Teva to Divest 14 Projects to Save $200M

October 6, 2014 8:56 am | News | Comments

Teva has identified 14 pipeline projects for discontinuation or divestment. These projects amount to more than $150 million in R&D costs in 2015 and in excess of $200 million for each of 2016 and 2017. These cost savings will be directed, in part, to increasing resources in Teva's core therapeutic areas, while another part of which will support the company's efficiency objective.

Big Cities Take Aim at Prescription Painkillers

September 16, 2014 2:25 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.      

Advertisement

UK High Court Gives Positive Judgment in Teva's Patent Case Against AstraZeneca

September 3, 2014 8:33 am | News | Comments

Teva Pharmaceutical announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART ( S ingle inhaler M aintenance A nd R eliever T herapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort®.

Teva Completes Acquisition of Labrys

July 21, 2014 8:15 am | News | Comments

The acquisition of Labrys brings to Teva LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), which is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine.  

Arena Pharmaceuticals to Market and Supply BELVIQ in Israel

July 21, 2014 8:12 am | News | Comments

Arena Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ with Teva Pharmaceutical Industries Limited's local Israeli subsidiary, Abic Marketing Limited.

FDA Approves Expanded Label for AZILECT®

June 9, 2014 8:14 am | News | Comments

Teva Pharmaceutical Industries today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for AZILECT ® (rasagiline tablets) from monotherapy and adjunct to levodopa (LD) to now include adjunct to dopamine agonists (DAs).

Chicago Sues Over Painkiller Marketing

June 3, 2014 3:39 pm | by CARLA K. JOHNSON, AP Medical Writer | News | Comments

The lawsuit filed Monday in Cook County Circuit Court states the city has paid nearly $9.5 million for filling opioid prescriptions since 2007. It alleges the pharmaceutical companies' marketing of opioids for long-term use to treat non-cancer pain was false, misleading and "unsupported by science."

Advertisement

Teva to Acquire Labrys Biologics

June 3, 2014 8:15 am | News | Comments

Teva will acquire Labrys for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones. Potential peak sales for LBR-101 are estimated to reach $2 to $3 billion.

Teva Announces New Organizational Structure and Senior Leadership Changes

June 2, 2014 3:47 pm | News | Comments

Teva Pharmaceutical Industries has announced a new organizational structure and related executive positions, designed to achieve seamless global integration, focus and effectiveness across the company. The changes will become effective July 1st.

FDA Approves First Generic Versions of Celecoxib

May 30, 2014 4:10 pm | News | Comments

The FDA today approved the first generic versions of Celebrex (celecoxib) capsules, a treatment for rheumatoid arthritis, osteoarthritis, short-term (acute) pain, and other conditions.           

Teva Receives FDA Approval for QVAR® with Dose Counter

May 23, 2014 8:36 am | News | Comments

Teva Pharmaceutical Industries announced that the FDA has approved the use of QVAR® (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients five years of age and older.

California Counties Sue Over Painkiller Marketing

May 22, 2014 3:18 pm | by PAUL ELIAS, Associated Press | News | Comments

Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.         

FDA Approves Teva’s SYNRIBO® for Injection for Home Administration

May 5, 2014 8:18 am | News | Comments

Teva Pharmaceutical has announced that the FDA has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use.   

Actavis Sues FDA Regarding Delay of Generic Celebrex Approval

April 29, 2014 8:29 am | News | Comments

Actavis announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the FDA challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.

Teva and Takeda to Commercialize Rasagiline for Parkinson’s Disease Treatment in Japan

April 28, 2014 8:18 am | News | Comments

Developed by Teva, rasagiline tablets are approved in over 40 countries for the treatment of Parkinson’s disease. Teva developed this product and received its first approval in 2005 in Israel and Europe, and is currently working towards the acquisition of marketing approval of this product in Japan.

Court Declines to Block Drug Ruling in Patent Case

April 18, 2014 4:35 pm | by The Associated Press | News | Comments

The Supreme Court has declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals. The order Friday from Chief Justice John Roberts is a victory for rivals challenging the maker of the drug Copaxone, Teva...

Teva Launches Generic Fish Oil Drug

April 8, 2014 11:38 am | by Associated Press | News | Comments

Teva Pharmaceutical Industries said Tuesday it is now selling a generic version of the heart medication Lovaza, which is used to treat high triglyceride levels.                        

Supreme Court Takes Up Drug Company Dispute

March 31, 2014 10:11 am | News | Comments

The justices agreed Monday to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.      

Court Upholds Mylan's Patents on Perforomist Inhalation Solution

March 25, 2014 7:26 am | News | Comments

Mylan Inc. has announced the United States District Court for the Northern District of West Virginia issued a decision upholding the validity of all patents asserted by Mylan, protecting Perforomist (formoterol fumarate) Inhalation Solution.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading